The best example pertains to the clinically actionable marker UGT1A1*28, which is associated with reduced UGT1A1 activity and irinotecan-induced severe neutropenia [16,90] (Figure 2). This evidence concerns the gene UGT1A1 and Decreased total neutrophil count.